A Hospital Based Survey on Lung Cancer Related-pain in Northern China
Clinical Characteristics, Evaluation and Management of Lung Cancer Related-pain in Northern China: a Hospital-based Cross-sectional Study
1 other identifier
observational
2,000
0 countries
N/A
Brief Summary
This cross-sectional study, utilizing two sets of questionaire designed for patients and physicians respectively, aims at the epidemiology, the clinical features, and the current status of evaluation and management of lung cancer related pain in 20 participating hospitals in Northern China.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P75+ for all trials
Started Jun 2017
Shorter than P25 for all trials
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
Study Start
First participant enrolled
June 1, 2017
CompletedFirst Submitted
Initial submission to the registry
June 14, 2017
CompletedFirst Posted
Study publicly available on registry
June 16, 2017
CompletedPrimary Completion
Last participant's last visit for primary outcome
September 1, 2017
CompletedStudy Completion
Last participant's last visit for all outcomes
September 1, 2017
CompletedJune 16, 2017
June 1, 2017
3 months
June 14, 2017
June 15, 2017
Conditions
Outcome Measures
Primary Outcomes (1)
Prevalence of cancer-related pain in lung cancer patients in 20 hospitals in northern China
the proportion of self-reported pain related to cancer affecting the enrolled lung cancer patients over the past 24 hours
24 hours
Eligibility Criteria
This is a cross-sectional study of clinical features (including prevalence, intensity and impact on life) of cancer-related pain in all lung cancer patients visiting the 20 participating hospitals in northern China on the designated day in July 2017. Meanwhile, all physicians receiving lung cancer patients in these hospitals are also enrolled to evaluate current management of lung cancer related pain in northern China. The patients will be identified in both outpatient clinics and inpatient wards of the involved hospitals. Informed consent will be obtained from participating patients and those who are not willing to provide pain information of interest and refuse to sign the ICF will be excluded.
You may qualify if:
- The patient questionaire
- All patients (outpatient and inpatient) diagnosed with lung cancer visiting the participating hospitals on the designated day of investigation
- Informed consent must be obtained from the participating patients
- The physician questionaire
- All physicians who receive lung cancer patients (outpatient and inpatient) in the participating hospitals on the designated day of investigation
Contact the study team to confirm eligibility.
Sponsors & Collaborators
- Chinese Academy of Medical Scienceslead
- Peking University Cancer Hospital & Institutecollaborator
- Chinese PLA General Hospitalcollaborator
- Beijing Chest Hospitalcollaborator
- 307 Hospital of PLAcollaborator
- Peking Union Medical College Hospitalcollaborator
- Beijing Chao Yang Hospitalcollaborator
- Peking University Third Hospitalcollaborator
- Peking University First Hospitalcollaborator
- The Hospital of Shunyi District Beijingcollaborator
- Daxing Hospital Beijingcollaborator
- Peking University Third Hospital Yanqing Hospitalcollaborator
- Tianjin Medical University Cancer Institute and Hospitalcollaborator
- Tianjin Medical University General Hospitalcollaborator
- Hebei Medical University Fourth Hospitalcollaborator
- Henan Cancer Hospitalcollaborator
- Shanxi Province Cancer Hospitalcollaborator
- Inner Mongolia People's Hospitalcollaborator
- The First Affiliated Hospital of Zhengzhou Universitycollaborator
- 309th Hospital of Chinese People's Liberation Armycollaborator
MeSH Terms
Conditions
Condition Hierarchy (Ancestors)
Central Study Contacts
Study Design
- Study Type
- observational
- Observational Model
- OTHER
- Time Perspective
- CROSS SECTIONAL
- Sponsor Type
- OTHER
- Responsible Party
- PRINCIPAL INVESTIGATOR
- PI Title
- Vice president of National Cancer Center Chinese Academy of Medical Sciences
Study Record Dates
First Submitted
June 14, 2017
First Posted
June 16, 2017
Study Start
June 1, 2017
Primary Completion
September 1, 2017
Study Completion
September 1, 2017
Last Updated
June 16, 2017
Record last verified: 2017-06
Data Sharing
- IPD Sharing
- Will not share